<DOC>
	<DOCNO>NCT01523301</DOCNO>
	<brief_summary>The purpose study show superiority Rotigotine placebo improvement depressive symptom subject idiopathic Parkinson 's disease .</brief_summary>
	<brief_title>Rotigotine Versus Placebo Evaluate Efficacy Depressive Symptoms Idiopathic Parkinson 's Disease Patients</brief_title>
	<detailed_description>The study include maximum 2-week Screening Period , maximum 4-week Titration Period early-stage Parkinson 's disease maximum 7-week Titration Period advanced-stage Parkinson 's disease , 8-week Maintenance Period , maximum 6-day De-escalation Period early-stage Parkinson 's disease maximum 12-day De-escalation Period advanced-stage Parkinson 's disease 30-day Safety Follow-Up Period . The maximum study duration individual subject early-stage Parkinson 's disease advanced-stage Parkinson 's disease 19 week 23 week , respectively .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Male female subject ≥ 20 year old Subjects diagnose idiopathic Parkinson 's disease ( accord United Kingdom Parkinson 's Disease Society Brain Bank Diagnostic Criteria Parkinson 's disease ) modify Hoehn Yahr Scale stag IIII ; motor fluctuation , dyskinesia , stable motor symptom least 4 week prior Screening Visit judge local investigator Subject Beck Depression Inventory II ( BDIII ) score ≥ 16 evidence depression rating scale study Parkinson 's disease ( Schrag A et al , 2007 ) Subject MiniMental State Examination ( MMSE ) score ≥ 24 If subject take Levodopa ( LDOPA ) derivative , Monoamine Oxidase ( MAO ) Binhibitors , anticholinergic agent , CatecholOMethyl Transferase ( COMT ) inhibitor NMethylDAspartate ( NMDA ) antagonist , he/she must stable dose least 28 day prior Screening Visit If subject take antidepressant drug selective serotonin reuptake inhibitor ( SSRIs ) , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , bupropion , tricyclic antidepressant ( TCAs ) , he/she must stable dose least 28 day prior Screening Visit maintain dose duration trial Subject medical psychiatric condition ( ie , bipolar disorder , dementia , hallucination psychosis ) , opinion investigator , could jeopardize would compromise subject 's ability participate study Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( 'Yes ' ) either Question 4 Question 5 CSSRS Screening ( Visit 1 ) Current psychotherapy behavior therapy participate study Subject receive electroconvulsive therapy within 12 week Screening Visit Subject receive dopamine agonist within 28 day Screening Visit Subject receive neuroleptic , methylphenidate , reserpine , alphamethyldopa , metoclopramide , levosulpiride amphetamine derivative within 28 day Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
	<keyword>Depressive Symptom</keyword>
	<keyword>Idiopathic Parkinson 's disease</keyword>
</DOC>